Sentence,class,file
"Adherence  rates among seven different chronic conditions ranged from 36.8% to 80%, with 65.4%  of diabetes patients adhering to their medication.5 A systematic review published in 2004  found that between 36% and 93% of diabetes patients took the prescribed amount of  oral hypoglycemic agents (OHA), and adherence to insulin ranged from 62% to 64%.1  According to current evidence, these rates have changed little over the past 10 years.2  This, together with the growing incidence of T2DM patients needing medication, makes  patient adherence a central part of effective diabetes management.6correspondence: gerda längst Department of general Practice and  health services research, University  hospital of heidelberg, Vossstrasse 2,  D-69115 heidelberg, germany Tel +49 6221 56 35559 Fax +49 6221 56 1972 email g erda.laengst@med.uni-heidelberg.d e Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Längst et al Running head recto: Medication information in diabetes care DOI: http://dx.doi.org/10.2147/PPA.S88357",Non-OADS,/arxiv_data1/oa_pdf/96/20/ppa-9-1431.PMC4612137.pdf
"study participants and recruitment Focus groups were conducted as part of a larger research  project called INFOPAT (Information technologies for  patient-centered healthcare, 2012–2016, http://www.infopat.",Non-OADS,/arxiv_data1/oa_pdf/96/20/ppa-9-1431.PMC4612137.pdf
Available from: http://www.akdae.,Non-OADS,/arxiv_data1/oa_pdf/96/20/ppa-9-1431.PMC4612137.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/96/20/ppa-9-1431.PMC4612137.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2015:9 1443–1458Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  1443OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S8802 2Patients’ and physicians’ preferences for type 2   diabetes mellitus treatments in spain and Portugal:  a discrete choice experiment carlos Morillas1 rosa Feliciano2 Pablo Fernández catalina3 carla Ponte4 Marta Botella5 João rodrigues6 enric esmatjes7 Javier lafita8 luis lizán9 ignacio llorente10 cristóbal Morales11 Jorge navarro-Pérez12 Domingo Orozco-Beltran13 silvia Paz9 Antonio ramirez de Arellano14 cristina cardoso15 Maribel Tribaldos causadias9 1hospital Universitario Dr Peset,   Valencia, spain; 2UsF são Domingos,   santarém, Portugal; 3hospital Montecelo  de Pontevedra, galicia, spain; 4UsF Porta  do sol, Matosinhos, Portugal; 5hospital  Universitario Principe de Asturias, Madrid,   spain; 6UsF serra da lousã, lousã, Portugal;   7hospital clinic, Barcelona, spain; 8hospital  de navarra, navarra, spain; 9Outcomes’10,   Universidad Jaume i, castellón, spain;   10hospital Universitario nuestra señora  de la candelaria, canarias, spain; 11hospital  Universitario Virgen de la Macarena, sevilla,   spain; 12incliVA, ciBeresP , Universidad de  Valencia, Valencia, spain; 13sociedad española  de Medicina Familiar y comunitaria,   Valencia, spain; 14novo nordisk eU-heOr   europe, Madrid, spain; 15novo nordisk,   lisbon, PortugalObjective:  To assess Spanish and Portuguese patients’ and physicians’ preferences regarding  type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain  benefits or avoid side effects.",Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
"The prevalence of type 2 diabetes mellitus (T2DM) in Spain  has been projected between 12.5%2 and 13.8%,3 while in Portugal the prevalence has  been estimated to be 7.2%.4 According to the Global estimates of diabetes prevalence correspondence: Antonio ramirez de  Arellano novo nordisk Pharma sA, Via de los  Poblados, 3, Parque empresarial cristalia,  Edificio 6 – 4a Planta, 28033 Madrid, spain Tel +34 913 349 800 email www.novonordisk.e s Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Morillas et al Running head recto: Preferences for type 2 diabetes mellitus treatments DOI: http://dx.doi.org/10.2147/PPA.S88022",Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
"Available from: http://www.ulsm.min-saude.pt/ResourcesUser/ Documentos/i018361.pd f. Accessed: November, 2013.",OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
Available from: http://censos.ine.pt/xportal/ xmain?xpid =CENSOS&xpgid =censos_quadros_populaca o  35.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
Available from: http://www.msssi.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
Available from: http://www.capacityplus.org/files/ resources/discrete-choice-experiment-user-guide.pd f  39.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
"Available from: http://CRAN.R-project.org/packagemlogi t. Accessed:  July, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
Available  from: http://onlinelibrary.wiley.com/doi/10.1111/bcp.12566/pd f  59.,Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/d1/9b/ppa-9-1443.PMC4612138.pdf
"Thirty-one children with virologic failure switched to a drug-sparing regimen within 6 months of follow-up (Supplementary Table 1S, http://links.lww.com/QAD/ A752).",Non-OADS,/arxiv_data1/oa_pdf/aa/65/aids-29-2109.PMC4612147.pdf
Available at http://www.niaid.nih.gov/lab sandresources/resources/daidsclinrsrch/documents/daidsaegra dingtable.pdf.,OADS,/arxiv_data1/oa_pdf/aa/65/aids-29-2109.PMC4612147.pdf
Available at http://www.cdc.gov/mmwr/preview/ mmwrhtml/00018871.htm.,Non-OADS,/arxiv_data1/oa_pdf/aa/65/aids-29-2109.PMC4612147.pdf
Available at http://www.cdc.gov/mmwr/PDF/rr/rr4312.pdf.,OADS,/arxiv_data1/oa_pdf/aa/65/aids-29-2109.PMC4612147.pdf
http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/CosmeticDevices/WrinkleFi llers/default.htm.,Non-OADS,/arxiv_data1/oa_pdf/bb/e2/spa-75-258.PMC4612148.pdf
http://en.wikipedia.org/wiki/Central_retinal_artery.,Non-OADS,/arxiv_data1/oa_pdf/bb/e2/spa-75-258.PMC4612148.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.193 Clinical and Molecular Hepatology 2015;21:193-199 Review Corresponding author :  Jisu Li  Liver Research Center, Rhode Island Hospital, The Warren Alpert Medical  School of Brown University, Providence, 55 Claverick Street, Room 424,  Providence, RI 02903, USA Tel: +1-401-444-7387, Fax: +1-401-444-2939 E-mail: Ji_su_li_md@brown.edu Shuping Tong Liver Research Center, Rhode Island Hospital, The Warren Alpert Medical  School of Brown University, Providence, 55 Claverick Street, Room 424,  Providence, RI 02903, USA Tel: +1-401-444-7365, Fax: +1-401-444-2939 E-mail: shuping_tong_md@brown.eduAbbreviations:   cccDNA, covalently closed circular DNA; CPD, carboxypeptidase D;  DHBV, duck hepatitis B virus; DMSO, dimethyl sulfoxide; GLDC; glycine  decarboxylase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface  antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;   HDV, hepatitis delta virus; HSPG, heparan sulfate proteoglycans;   L protein, large envelope protein; M protein, middle envelope protein;  NTCP , sodium taurocholate cotransporting polypeptide;   PEG, polyethylene glycol; S protein: small envelope protein Received :  May 5, 2015 /  Accepted :  Aug. 15, 2015INTRODUCTION  An estimated 350 million people worldwide are chronically in - fected with hepatitis B virus (HBV), which greatly increases their risk to develop liver cirrhosis and hepatocellular carcinoma (HCC).",Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
"(Clin Mol Hepatol 2015;21:193-199) Keywords:  Hepatitis B virus; Carboxypeptidase D; Glycine decarboxylase; heparan sulfate proteoglycans; Sodium  taurocholate cotransporting polypeptide Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
"194 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.193Clin Mol Hepatol Volume _21  Number _3  September 2015logues target DNA replication, a late step in HBV lifecycle.",Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
HBV receptor  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.193fection.,Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
"196 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.193Clin Mol Hepatol Volume _21  Number _3  September 2015HepaRG cells, and this was attributed to its augmentation of HBV  binding to HSPG.22 Although the preS1 domain was initially  thought to be responsible for HSPG interaction,22  further study  revealed that the negatively charged HSPG interacts with two ba - sic residues (R122 and K141) in the “a” determinant of the S do - main.24 Thus, anti-S antibodies neutralize HBV infectivity by block - ing virus attachment to cell surface via HSPG.",Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
"HBV receptor  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.193Further evidence supporting NTCP as a major  HBV receptor in vitro NTCP, a transmembrane protein localized on the basolateral  (blood facing) side of hepatocytes, is a key transporter of bile salt  from blood to the liver.27 Since the 2012 eLife paper by Yan et  al.,26 a flurry of papers have been published by others which di - rectly or indirectly support NTCP as an HBV receptor (see Table 2  for explanations).28-40 Also, Dr. Li’s own group has extended their  findings.41-44 NTCP binding to myristoylated preS1 residues 2-48  could explain why antibodies against C-terminal part of this se - quence is neutralizing (the N-terminus is probably masked by my - ristoylation), and probably also why myristoylation is essential for  infectivity (it probably partly mediates NTCP interaction by struc - tural mimicry of cholesterol).",Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
"198 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.193Clin Mol Hepatol Volume _21  Number _3  September 2015retroviral infection, etc).",Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
HBV receptor  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.19322.,Non-OADS,/arxiv_data1/oa_pdf/34/b9/cmh-21-193.PMC4612279.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.200 Clinical and Molecular Hepatology 2015;21:200-211 Review Corresponding author :  Vincent Wai-Sun Wong Department of Medicine and Therapeutics and State Key Laboratory  of Digestive Disease, The Chinese University of Hong Kong, 9/F, Clinical  Sciences Building, Prince of Wales Hospital, 30-32 Ngan Shing Street,  Shatin, Hong Kong Tel: +852 26323942, Fax: +852 26373852 E-mail: wongv@cuhk.edu.hkAbbreviations:   ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index;   AST, aspartate aminotransferase; CHB, chronic hepatitis B; CHC, chronic  hepatitis C; EGD,esophagogastroduodenoscopy; ELF, enhanced liver  fibrosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma;   HCV, hepatitis C virus; HR, hazard ratio; HVPG, hepatic vein pressure  gradient; LSM, liver stiffness measurement; NAFLD, non-alcoholic fatty  liver disease Received :  May 19, 2015 /  Accepted :  Aug. 15, 2015INTRODUCTION  Despite geographical differences, chronic liver diseases are  highly prevalent worldwide.",Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
"(Clin Mol Hepatol 2015;21:200-211) Keywords:  Transient elastography; FibroScan; FibroTest; Hepatocellular carcinoma; Varices Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
"Non-invasive tests for cirrhosis management http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200In addition, cirrhosis is not one single disease but encompasses  a broad spectrum of clinical condition ranging from compensated  disease to decompensated disease.",Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
"202 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200Clin Mol Hepatol Volume _21  Number _3  September 2015be highly accurate and is not affected by obesity, but machine  availability and the costs of examination can be prohibitive.21  These new techniques also have not been as extensively validated  as transient elastography.",Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
Non-invasive tests for cirrhosis management http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200Table 2.,Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
"204 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200Clin Mol Hepatol Volume _21  Number _3  September 2015another prospective cohort of 866 Japanese CHC patients  that the HRs of HCC were 17, 21, 26, and 46 in patients  with LSM at 10.1–15.0 kPa, 15.1–20.0 kPa, 20.1–25.0 kPa,  and >25.0 kPa, respectively, with reference to those with  LSM ≤ 10.0 kPa.31 These findings implied that LSM is a  useful parameter to estimate HCC risk in patients with  chronic liver disease across the etiologies despite different  carcinogenetic mechanisms.",Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
Non-invasive tests for cirrhosis management http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200Table 3.,Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
"206 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200Clin Mol Hepatol Volume _21  Number _3  September 2015 Author Etiology N Non-invasive tests Cutoff for varicesCutoff for  large varicesAUROC Sensitivity Specificity AST-to-platetlet ratio index 1.5 1.62OV 0.68;  High risk OV 0.67OV 59%; High risk OV  64%OV 64%; High risk OV   68% Cherian 201169Mixed 229 Child-Pugh score class B/C class B/Cnot reported for OV/ large OVOV-not reported; large  OV 95%OV-not reported; large  OV 25.7% Spleen diameter 150 mm 160 mmOV-not reported;  large OV 0.63OV-not reported; large  OV 67%OV-not reported; large  OV 54.7% Platelet count 100,000/uL 90,000/uLOV-not reported;  large OV 0.70OV-not reported; large  OV 59%OV-not reported; large  OV 64% Portal vein diameter 13 mm - OV-not reported OV-not reported OV-not reported Eslam 201367Mixed 280Adiponectin + platelet  count + homeostasis  model assessment of insulin  resistance (HOMA-IR)Adepoectin 19.2 ug/L  platelet 100 x103  HOMA IR 4-estimation cohort 0.88                     -validation cohort 0.80-estimation cohort 91% -validation cohort 87%-estimation cohort  87%         -validation  cohort 82% T aourel et al.",Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
Non-invasive tests for cirrhosis management http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200objective and accurate diagnosis of cirrhosis (Table 1).,Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
"208 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200Clin Mol Hepatol Volume _21  Number _3  September 2015portal hypertension, it is logical to consider their application in  selecting patients for EGD.",Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
Non-invasive tests for cirrhosis management http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200liver histology markers.,Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
210 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.200Clin Mol Hepatol Volume _21  Number _3  September 201537.,Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
Non-invasive tests for cirrhosis management http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.20062.,Non-OADS,/arxiv_data1/oa_pdf/67/86/cmh-21-200.PMC4612280.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.212 Clinical and Molecular Hepatology 2015;21:212-219 Review Corresponding author :  Vijay H. Shah Gastroenterology Research Unit, Department of Gastroenterology and  Hepatology, Mayo Clinic, 200 First ST SW, Rochester, MN 55905, USA Tel: +1-507-255-6028, Fax: +1-507-255-6318 Email: shah.vijay@mayo.eduAbbreviations:   ANI, alcoholic/nonalcoholic steatohepatitis index; MELD, Model For  End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PNPLA3,  Patatin-like phospholipase domain-containing protein 3; TMA,  trimethylamine; TMAO, trimethylamine-N-oxide Received :  May 14, 2015 /  Accepted :  Aug. 15, 2015EPIDEMIOLOGY Alcoholic liver disease continues to be a significant source of  healthcare expenditure with increasing rates of hospitalization  and increasing costs per hospitalization in large part from complica - tions such as sepsis, acute renal failure, and gastrointestinal (GI)  bleeding in patients with advanced forms of alcoholic liver disease.1  There is an increasing trend of transplantation for alcoholic liver dis - ease with an approximately 45% increase in transplant registrations  in the United States.2 This is likely to continue to increase in the set - ting of diminishing cases of hepatitis C-related cirrhosis over the fu - ture decades.",Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
"(Clin Mol Hepatol 2015;21:212-219) Keywords:  Liver transplantation; Alcoholic hepatitis; Corticosteroids; Alcohol Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
"213 Vijay H. Shah Managing alcoholic liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.212crime, and increasing unplanned pregnancy.",Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
"Laboratory markers can  be helpful in predicting excess alcohol consumption, and some of  them have been compiled together with demographic factors in  the alcohol/nonalcoholic steatohepatitis index (ANI) which is orig - inally designed to distinguish alcohol from nonalcoholic steato - hepatitis (NASH) in individuals who have steatosis on a liver biop - sy.8 This model uses the mean corpuscular volume (MCV), the  asparate aminotransferase (AST)/alanine aminotransferase (ALT)  ratio, the body mass index (BMI) and gender with a nomogram  that’s available at a web calculator (http://www.mayoclinic.org/ medical-professionals/model-end-stage-liver-disease/alcoholic-liv - er-disease-nonalcoholic-fatty-liver-disease-index) to allow predic - tion of whether liver abnormalities may be relating to alcohol or  non-alcohol related etiologies.8 We are now realizing that many  patients may have a combination of both of these conditions as  well as factored in the development of steatosis and liver prob - lems, and even if the diagnosis of excess alcohol consumption is  made, this may not always equate with alcoholic hepatitis.",Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
214 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.212Clin Mol Hepatol Volume _21  Number _3  September 2015jority of cases certainly would not require a liver biopsy.,Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
The MELD score also has easily available calcula - tors now (http://www.mayoclinic.org/medical-professionals/mod - el-end-stage-liver-disease/meld-score-90-day-mortality-rate- alcoholic-hepatitis) and cut-points can be based on the toxicity of  the proposed treatment.,Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
215 Vijay H. Shah Managing alcoholic liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.212tered care models are underdevelopment to better manage this  population.,Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
"216 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.212Clin Mol Hepatol Volume _21  Number _3  September 2015months, where no beneficial effect was seen.",Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
"217 Vijay H. Shah Managing alcoholic liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.212alcohol consumption has occurred until very recently, there is very  few of those individuals who will indeed qualify for this aggres - sive-type treatment.",Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
"218 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.212Clin Mol Hepatol Volume _21  Number _3  September 2015pound that is being studied is called Anakinra, which is an inhibi - tor of the interleukin-1 beta receptor.32 When hepatocytes are  damaged by alcohol, they release interleukin-1 beta, and this  stimulates activation of hepatic stellate cells and also recruitment  of the inflammatory white blood cells, and Anakinra, by blocking  the receptor for interleukin-1 beta on these cells, is able to reduce  the effects of this interleukin-1 which has been termed the inflam - masome response.",Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
219 Vijay H. Shah Managing alcoholic liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.21218.,Non-OADS,/arxiv_data1/oa_pdf/4a/ad/cmh-21-212.PMC4612281.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.220 Clinical and Molecular Hepatology 2015;21:220-229 Review Corresponding author :  Ju-Seog Lee Department of Systems Biology, Unit 950, The University of Texas MD  Anderson Cancer Center, Houston, TX 77054, USA Tel: +1-713-834-6154, Fax: +1-713-563-4235 E-mail: jlee@mdanderson.orgAbbreviations:   ARID1A, AT-rich interactive domain 1A; ARID2, AT-rich interactive  domain 2; AXIN1, axis inhibitor 1; CTNNB1, catenin (cadherin-associated  protein) beta 1; HCC, hepatocellular carcinoma; KEAP1, Kelch-like ECH- associated protein 1; NFE2L2, nuclear factor erythroid 2-like 2; NGS,  next-generation sequencing; TERT, telomerase reverse transcriptase;  TP53, tumor protein 53; WNT, wingless-type MMTV integration site  family Received :  Feb. 2, 2015 /  Accepted :  Aug. 9, 2015INTRODUCTION  Hepatocellular carcinoma (HCC) is one of the most common  cancers in the world, accounting for an estimated 600,000 deaths  annually.1 HCC is common in Southeast Asia and sub-Saharan Af - rica, but the incidence rate of HCC has also increased in the Unit - ed States and Western Europe over the past 25 years, and inci - dence and mortality rates of HCC are likely to double over the  next 10 to 20 years.2-4  Although much is known about both the cellular changes that  lead to HCC and the etiologic agents responsible for most cases  of HCC (i.e., hepatitis B and C viral infections and alcohol abuse),  the molecular pathogenesis of HCC is not well understood .5-7  Moreover, the severity of HCC, the lack of good diagnostic mark - ers and treatment strategies, and clinical heterogeneity make  management of the disease a major challeng e.7,8 Patients with HCC have a highly variable clinical cour se,6,9 indi- cating that HCC comprises several biologically distinctive sub - groups.",Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
"(Clin Mol Hepatol 2015;21:220-229) Keywords:  Hepatocellular carcinoma; Cancer genomics; Somatic mutations; TERT; TP53 Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
"221 Ju-Seog Lee Mutations in HCC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220tein kinases and protei nase.15,16 Treatment with these targeted  drugs can more efficiently alter the natural history of disease and  reduce mortality.",Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
222 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220Clin Mol Hepatol Volume _21  Number _3  September 2015telomerase regulation.,Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
"223 Ju-Seog Lee Mutations in HCC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220TP53 (gain-of-function mutations), such as angiogenesis, me - tastasis, and resistance to standard therapies.52,53 A recent study demonstrated that the  TP53  mutations are  associated with  poor prognosis in HCC.47 In particular, hotspot  mutations such as R249S and V157F are strongly associated  with poor prognosis, indicating that these mutations can be  used as prognostic markers in HCC.",Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
224 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220Clin Mol Hepatol Volume _21  Number _3  September 2015complex.,OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
"225 Ju-Seog Lee Mutations in HCC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220survival against oxidative stress.72-74 Under normal physiologic  conditions, intracellular levels of NFE2L2 are kept low by its cy - tosolic inhibitor, Kelch-like ECH-associated protein 1 (KEAP1),  which functions as an adaptor protein in the cullin 3-based E3  ligase complex that ubiquitinates NFE2L2 in the cytoplasm and  targets it for proteasomal degradation.",Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
"226 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220Clin Mol Hepatol Volume _21  Number _3  September 2015es must be devised to find actionable targets by systematically  integrating multiple genetic, epigenetic, and proteomic data  from HCC tumors, as demonstrated by the success of The Can- cer Genome Atlas projects in many cancers.86-93 Acknowledgements  The study was supported in part by the 2011 and 2012 cycles  of the MD Anderson Sister Institute Network Fund.",Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
227 Ju-Seog Lee Mutations in HCC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220sequencing.,OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
228 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220Clin Mol Hepatol Volume _21  Number _3  September 20152000;24:245-250.,Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
229 Ju-Seog Lee Mutations in HCC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.220characterization of gastric adenocarcinoma.,Non-OADS,/arxiv_data1/oa_pdf/25/bb/cmh-21-220.PMC4612282.pdf
"pISSN 2287-2728        eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.230 Clinical and Molecular Hepatology 2015;21:230-231 Editorial See Article on Page 257 Hepatocellular carcinoma (HCC) is the second leading cause  of cancer related death with increasing incidence.1 The standard  treatments of HCC consist of surgical resection, liver transplanta - tion, radiofrequency ablation and transarterial chemoemboliza - tion.",Non-OADS,/arxiv_data1/oa_pdf/33/d0/cmh-21-230.PMC4612283.pdf
"The P53 expression in hepatocellular carcinoma: influence  on the radiotherapeutic response of the hepatocellular  carcinoma Yu Rim Lee and Soo Young Park Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea  Keywords:  Hepatocellular carcinoma; Radiotherapy; P53 Corresponding author :  Soo Young Park Department of Internal Medicine, Kyungpook National University Hospital,  130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea Tel: +82-53-200-5519, Fax: +82-53-426-8773 E-mail: psyoung0419@gmail.comAbbreviations:   BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma Received :  Aug. 7, 2015 /  Revised :  Aug. 27, 2015  Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/33/d0/cmh-21-230.PMC4612283.pdf
P53 and HCC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.230Hep3B2.1-7 cells were less radiosensitive than other two cell lines.,Non-OADS,/arxiv_data1/oa_pdf/33/d0/cmh-21-230.PMC4612283.pdf
"GLOBOCAN 2012: Estimated Cancer  Incidence, Mortality and Prevalende Worldwide in 2012. WHO web site, <http://globocan.iarc.fr/Default.aspx> Accessed Aug. 5, 2015.",OADS,/arxiv_data1/oa_pdf/33/d0/cmh-21-230.PMC4612283.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.232 Clinical and Molecular Hepatology 2015;21:232-241 Original Article Corresponding author :  Yong-Han Paik Department of Medicine, Samsung Medical Center, Sungkyunkwan  University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul 06351,  Korea  Tel: +82-2-3410-3878, Fax: +82-2-3410-6983 E-mail: yh.paik@skku.edu Abbreviations:   ALT, alanine aminotransferase; AST, aspartate aminotransferase;  CRRT, continuous renal replacement therapy; Gr, grade; HE, hepatic  encephalopathy; HRS, hepatorenal syndrome; INR, international  normalized ratio; LT, liver transplantation; MELD, model of end- stage liver disease; PT, prothrombin time; SBP , spontaneous bacterial  peritonitis; SIRS, systemic inflammatory response syndrome Received :  Jul.",Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
"(Clin Mol Hepatol 2015;21:232-241) Keywords:  Acute-on-chronic liver failure; Chronic hepatitis B; Model for End-Stage Liver Disease; Liver transplantation Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
Prognosis of ACLF http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232features of ACLF are differentiated from those of acute liver fail - ure.4 HBV flares occur in 40-50% of hepatitis B envelope antigen  (HBeAg)-positive CHB patients and in 15-30% of HBeAg-negative  CHB patients.,Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
"234 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232Clin Mol Hepatol Volume _21  Number _3  September 2015medicinal herbs (n=3), sepsis-related liver injury (n=5), and cryp - togenic causes (n=1)), 55 patients with coexistent malignancy  (hepatocellular carcinoma (n=54) and esophageal cancer (n=1)).",Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
Prognosis of ACLF http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232analysis.,Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
"236 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232Clin Mol Hepatol Volume _21  Number _3  September 2015received NAs; 11 (39%) with ETV, 10 (36%) with LAM, 2 with ad - efovir (ADV), 1 with a combination of LAM/ADV and 1 with a  combination of LAM/ETV/ADV.",OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
"Prognosis of ACLF http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232peared on the 7th day with an increase of 3 ( P=0.010), followed by  an increase of 4.8 on the 10th day ( P=0.000), and 5.5 on the 13th day  (P<0.001).",Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
238 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232Clin Mol Hepatol Volume _21  Number _3  September 2015Table 3.,Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
"Prognosis of ACLF http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232ascites (OR 6.71, P=0.012) and the aggravation of hepatic en - cephalopathy ( ≥grade III) during hospitalization (OR 15.41,  P=0.013).",Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
240 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232Clin Mol Hepatol Volume _21  Number _3  September 2015dicting the outcome of ACLF-HBV.,OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
Prognosis of ACLF http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.232Conflicts of Interest The authors have no conflicts to disclose.,Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
Fact sheet N°204 : Hepatitis B. Pub - lished August 2008.WHO web site <http://www.who.int/mediacen - ter/factsheets /fs204/en/> Accessed 2014.,Non-OADS,/arxiv_data1/oa_pdf/34/64/cmh-21-232.PMC4612284.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.242 Clinical and Molecular Hepatology 2015;21:242-248 Original Article Corresponding author :  Soo Young Park Division of Gastroenterology and Hepatology, Department of Internal  Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro,  Jung-gu, Daegu 41944, Korea.",Non-OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
"(Clin Mol Hepatol 2015;21:242-248) Keywords:  Chronic hepatitis B, Lamivudine resistance, Combination therapy, Entecavir, Tenofovir Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
"ETV and TDF in prior failure of LAM and ADV http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.242treatment option is one of main causes of the high prevalence of  genotypic resistance to NAs among CHB patients in Asian coun - tries.6 Especially, switching to ADV monotherapy instead of an  add-on therapy increased the number of CHB patients with multi - drug resistance or a suboptimal response to NA combination ther - apy.6-9 Sequential ADV monotherapy after the emergence of LAM  resistance failed to achieve an adequate virologic response in up  to 25% of patients and additionally caused the development of  genotypic resistance.10,11 LAM and ADV combination therapy has  also failed to achieve complete response in approximately 70% of  LAM-resistant CHB patients.7,12 A suboptimal response to antiviral  therapy might result in a higher risk of developing resistance to  multiple NAs, leading to an increased risk of end-stage liver dis - ease and HCC.13-14 Therefore, most guidelines suggest that the  ideal treatment for CHB is to reduce the serum HBV DNA level to  below the detection limit of real-time polymerase chain reaction  (PCR).1,3 There is little consensus on the adequate antiviral therapy  for CHB patients showing a suboptimal response after LAM and  ADV combination therapy.",Non-OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
244 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.242Clin Mol Hepatol Volume _21  Number _3  September 2015and compared with a log-rank test.,OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
"ETV and TDF in prior failure of LAM and ADV http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.242presence of resistance mutation with LAM+ADV or LAM+ETV  (n=17, 57% vs. n=20, 61%; P=0.751).16 Virologic response The primary end-point, the proportion of patients who achieved  VR12, was significantly different between the two groups (26.7%  vs. 84.8%, P<0.001) (Table 2, Fig.",Non-OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
"246 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.242Clin Mol Hepatol Volume _21  Number _3  September 2015Both the ETV+ADV and ETV+TDF groups showed an initial rapid  reduction of serum HBV DNA level during the first 3 months (2.12  log10 IU/mL vs. 2.00 log10 IU/mL, P=0.731).",Non-OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
"ETV and TDF in prior failure of LAM and ADV http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.242with NA-resistant HBV who showed suboptimal responses to the  combination of LAM and ADV (ETV+ADV, 26.7% vs. ETV+TDF,  84.8%).",OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
248 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.242Clin Mol Hepatol Volume _21  Number _3  September 2015  4.,Non-OADS,/arxiv_data1/oa_pdf/c3/da/cmh-21-242.PMC4612285.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.249 Clinical and Molecular Hepatology 2015;21:249-256 Original Article Corresponding author :  Moran Ki Department of Cancer Control and Policy, Graduate School of Cancer  Science and Policy, National Cancer Center, 323 ilsan-ro, ilsandong-gu,  Goyang 10408, Korea Tel: +82-31-920-2736, Fax: +82-50-4069-4908 E-mail: moranki@naver.comAbbreviations:   HCV, chronic hepatitis C; ICD,  International classification of diseases;  HBV, chronic hepatitis B; NHIS, national health insurance   Received :  Apr.",Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
"(Clin Mol Hepatol 2015;21:249-256) Keywords:  Hepatitis C virus; Prevalence; Adult; Geographic information systems; Republic of Korea Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
"250 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.249Clin Mol Hepatol Volume _21  Number _3  September 2015INTRODUCTION  The hepatitis C virus (HCV) infection was discovered fairly recently,  and HCV infection is now known to exhibit a higher rate of transition  into chronic infection, compared to hepatitis B virus (HBV) infection.",Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
Prevalence of hepatitis C virus infection in Korea http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.249final day of treatment in the relevant year.,Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
252 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.249Clin Mol Hepatol Volume _21  Number _3  September 2015typically had high prevalences.,Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
Prevalence of hepatitis C virus infection in Korea http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.249in these high-prevalence regions.,Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
"254 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.249Clin Mol Hepatol Volume _21  Number _3  September 2015cludes recovered patients who had HCV infection in the past and  for the case of community-based cohort, although it is possible to  estimate prevalence in a specified region, it requires a large-scale  cohort with at least 100,000 people because HCV infection has low prevalence.",Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
"Prevalence of hepatitis C virus infection in Korea http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.249studies from the 1990s, reported that the prevalence among Ko - rean adults who are >40 years old was 1.68% (95% CI: 1.51- 1.86) and that the prevalence among men (0.77%, 95% CI: 0.72- 0.83) was slightly lower than the prevalence among women  (1.06%, 95% CI: 0.97-1.16).10 These results are noticeably differ - ent from the findings of the present study.",Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
"256 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.249Clin Mol Hepatol Volume _21  Number _3  September 2015Among the 16 cities and provinces that were examined, Jeju ex - hibited the greatest increase in the age-adjusted prevalence, with a  rapid increase from 0.15% in 2005 to 0.23% in 2012.",OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
SUPPLEMENTARY MATERIALS Supplementary data related to this article is available online   http://e-cmh.org/suppl/chm-21-3-249-s001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/3b/7b/cmh-21-249.PMC4612286.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.257 Clinical and Molecular Hepatology 2015;21:257-267 Original Article Corresponding author :  Maria F. Botelho Biophysics Unit, Faculty of Medicine, University of Coimbra, Azinhaga de  Santa Comba – Celas, 3000-541 Coimbra, Portugal Tel: +351 239480200, Fax: +351 239480217 E-mail: mfbotelho@fmed.uc.ptAbbreviations:   HCC, Hepatocellular Carcinoma; p-P53, phosphorylated P53 protein;  ROS, reactive oxygen species Received :  Apr.",Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"(Clin Mol Hepatol  2015;21:257-267) Keywords:  Hepatocellular carcinoma; Iodine-131; Radiotherapy; P53 Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"258 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257Clin Mol Hepatol Volume _21  Number _3  September 2015cess of radiotherapy against cancer depends on its ability to kill  tumor cells, while preserving the adjacent normal tissue.4,5 Radio - therapy can be external and internal.",Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
P53 expression in radiotherapy response:  in vitro  studies http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257washed afterwards with phosphate buffered saline (PBS).,Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"260 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257Clin Mol Hepatol Volume _21  Number _3  September 2015Statistical analysis Cell survival curves were obtained using Origin Pro v8.0, fitting  the experimental data to two models: for lower doses, the data  was fitted to a linear-quadratic model, according to the equation  SF=e-αD-βD2; for higher radiation doses, we fitted the data to a  linear model, using SF=e-C-αD.",OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"P53 expression in radiotherapy response:  in vitro  studies http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257ROS and reduced glutathione production,  mitochondrial membrane potential and cell cycle  Regarding to the intracellular peroxide concentrations in cells  exposed to internal 1 Gy irradiation was observed an increase in intracellular peroxide concentration in Hep3B2.1-7 cell line  (P=0.015), relative to control cell population (Fig.",OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"262 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257Clin Mol Hepatol Volume _21  Number _3  September 2015cells ( P=0.013) as well as for 20 Gy ( P=0.016), in comparison to  control.",OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
P53 expression in radiotherapy response:  in vitro  studies http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257cell lines.,Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
264 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257Clin Mol Hepatol Volume _21  Number _3  September 2015 Figure 6 .,Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"P53 expression in radiotherapy response:  in vitro  studies http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257the exposure to iodine-131, cell survival and cell viability were  evaluated.",OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
266 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257Clin Mol Hepatol Volume _21  Number _3  September 2015REFERENCES   1.,Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"GLOBOCAN 2012: Estimated Cancer  Incidence, Mortality and Prevalende Worldwide in 2012. WHO web  site, <http://globocan.iarc.fr/Default.aspx> Accessed 2011.",Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
P53 expression in radiotherapy response:  in vitro  studies http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.2572006;20:1-15.,Non-OADS,/arxiv_data1/oa_pdf/88/71/cmh-21-257.PMC4612287.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.268 Clinical and Molecular Hepatology 2015;21:268-278 Original Article Corresponding author :  Changik Jo International Trade & Business, Hallym University College of International  Studies, 1 Hallymdaehak-gil, Chuncheon 24252, Korea Tel: +82-33-248-1890, Fax: +82-33-256-3424 E-mail: cjo@hallym.ac.krAbbreviations:   CBA, cost-benefit analysis; CL, conditional logit; DCE, discrete choice  experimentation; FE, fixed effects; IIA, independent of irrelevant  alternatives; IID, independent and identically distributed; ML, mixed  logit; MRS, marginal rate of substitution; MWTP , marginal willingness to  pay; NHIS, National health insurance service; OMEP , orthogonal main  effects plan; PE, preference elicitation; RUT, random utility theory; SES,  socioeconomic status Received :  May 1, 2015 /  Revised :  Jul.",Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
"(Clin Mol  Hepatol 2015;21:268-278) Keywords:  Preference elicitation; Marginal willingness to pay; Marginal rate of substitution; Conditional logit; Mixed logit Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
269 Donghun Cho and Changik Jo Marginal willingness to pay of insurance premium for liver cancer http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268moil in sustaining the policies in medical and health care.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
270 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268Clin Mol Hepatol Volume _21  Number _3  September 2015solution.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
271 Donghun Cho and Changik Jo Marginal willingness to pay of insurance premium for liver cancer http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268treatment protocol and costs of liver cancers listed in liver cancer  registration statistics and the number of patients in the group (see  Table 1).,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
"272 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268Clin Mol Hepatol Volume _21  Number _3  September 2015ij ij ijV U    ij ik ik ij ik ik ij ij V V V V     or           ] Pr[] Pr[ik ij ij ik ik ij VV U U      K kijij ik VV P 1) exp() exp(  ij iji ij ij ij z x U        i i K kik iki ik ikij iji ij ij ij d f z xz xP  ) ( ) exp() exp(* 1   (4) where Vij =β’X.14 Here, a vector of X represents attributes and  observed individual characteristics.",OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
"273 Donghun Cho and Changik Jo Marginal willingness to pay of insurance premium for liver cancer http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268ternatives (options A, B, or opt out).",Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
274 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268Clin Mol Hepatol Volume _21  Number _3  September 2015ent.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
275 Donghun Cho and Changik Jo Marginal willingness to pay of insurance premium for liver cancer http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268use ‘hybrid’ CL model along with mixed logit.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
276 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268Clin Mol Hepatol Volume _21  Number _3  September 2015which uses ML model.,OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
277 Donghun Cho and Changik Jo Marginal willingness to pay of insurance premium for liver cancer http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268inarguably a crucial source and its amount and adjustment should  be determined on the evidence basis that sufficiently reflects the  willingness to pay as well as affordability of the premium payers.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
Conflicts of Interest The authors have no conflicts to disclose.SUPPLEMENTARY MATERIALS Supplementary data related to this article is available online   http://e-cmh.org/suppl/chm-21-3-268-s001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
<http://seer.cancer.gov/statfacts/html/livibd.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
278 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.268Clin Mol Hepatol Volume _21  Number _3  September 2015Applications of simulation methods in environmental economics.,Non-OADS,/arxiv_data1/oa_pdf/c0/91/cmh-21-268.PMC4612288.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.279 Clinical and Molecular Hepatology 2015;21:279-286 Original Article Corresponding author :  Mi-Suk Park Department of Radiology, Severance Hospital, Yonsei University College  of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-7400, Fax: +82-2-393-3035 E-mail: radpms@yuhs.acAbbreviations:   AASLD, the American Association for the Study of Liver Diseases; AFP ,  alpha-fetoprotein; ALT, alanine aminotransferase; APASL, the Asian  Pacific Association for the Study of the Liver; EASL,the European  Association for the Study of Liver; HBV, hepatitis B virus; HCC,  hepatocellular carcinoma; HCV, hepatitis C virus; INR,International  Normalized Ratio; PIVKA-II, protein induced by vitamin K absence Received :  May 21, 2015 /  Revised :  Aug. 2, 2015 /  Accepted :  Aug. 13, 2015INTRODUCTION  Hepatocellular carcinoma (HCC) is an important public health  problem.",Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
"(Clin Mol Hepatol 2015;21:279-286) Keywords:  Hepatocellular carcinoma; Tumor burden; Follow-up studies; Liver neoplasm; Surveillance Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
"280 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.279Clin Mol Hepatol Volume _21  Number _3  September 2015reached on all three issues, the dilemmas faced by physicians car - ing for high-risk patients stem mainly from determining the opti - mal surveillance interval.8 The optimal surveillance interval is de - termined based on the tumor size and growth rate in order to  detect HCCs at a stage when treatment is likely to produce a  cure.9,10 While the ideal HCC surveillance interval is not known, in - tervals ranging from 3-12 months have been proposed.2,11,12 Cur- rently, the American Association for the Study of Liver Diseases  (AASLD), the European Association for the Study of Liver (EASL),  and the Asian Pacific Association for the Study of the Liver  (APASL) recommend that surveillance be conducted at 6-month  intervals.2 This recommendation is based on the assumption that  the HCC growth rate is similar in every patient.",Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
"Growth rate of hepatocellular carcinoma http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.279min, bilirubin, international normalized ratio (INR), serologic mark - ers of viral hepatitis, and HBV DNA.",Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
"282 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.279Clin Mol Hepatol Volume _21  Number _3  September 2015Seoul, Korea) and ribavirin (Viramid; Ilsung Pharmaceuticals,  Seoul, Korea).",Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
"Growth rate of hepatocellular carcinoma http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.279TVDT between the patients infected with HBV and those infected  with HCV ( P<0.001) but not between those with no hepatitis vi - rus infection and those with either HBV or HCV infection (no virus  vs. HBV, P=0.1226; no virus vs. HCV, P=0.2994; Fig.",Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
284 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.279Clin Mol Hepatol Volume _21  Number _3  September 2015spective studies.,Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
Growth rate of hepatocellular carcinoma http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.279enough nutrients for growth.32  The growth rate of HCC could be intimately intertwined with  the recall strategy for non-invasive HCC diagnosis.,Non-OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
286 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.279Clin Mol Hepatol Volume _21  Number _3  September 2015Hann HW.,OADS,/arxiv_data1/oa_pdf/b9/00/cmh-21-279.PMC4612289.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.287 Clinical and Molecular Hepatology 2015;21:287-294 Original Article Corresponding author :  Jung Gil Park Division of Gastroenterology and Hepatology, Department of Internal  Medicine, CHA Gumi Medical Center, CHA University, 12 Shinsi-ro 10-gil   Gumi 39295, Korea Tel: +82-54-450-9545, Fax: +82-54-450-9798 E-mail: gsnrs@naver.comAbbreviations:   AASLD, the American Association for the Study of Liver Diseases;  AFP , serum alpha fetoprotein; CR, complete remission; CT,  computed  tomography; EASL, European Association for the Study of the  Liver; HCC, hepatocellular carcinoma; PIVKA-II, protein induced by  vitamin K absence or antagonist-II; RFA, radiofrequency ablation;  SHARP , Sorafenib HCC Assessment Randomized Protocol trial; TACE,  transarterial chemoembolization; VEGFR, vascular-endothelial growth  factor Received :  Jul.",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
"(Clin Mol Hepatol 2015;21:287-294) Keywords:  Hepatocellular carcinoma; Complete remission; Sorafenib Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
"288 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.287Clin Mol Hepatol Volume _21  Number _3  September 2015Raf, vascular-endothelial growth factor (VEGFR)-2, VEGFR-3,  platelet-derived growth factor - β, Flt-3, and c-Kit that inhibit mo - lecular pathogenesis, angiogenesis, and tumor cell proliferation.5-7  The rationale for the use of sorafenib in patients with advanced  HCC is based on two large 3-phase clinical trials, namely, the  Sorafenib HCC Assessment Randomized Protocol (SHARP) and the  Asia-Pacific (conducted in the Asia-Pacific region) trials.8,9 Cur- rently, sorafenib is the sole systemic agent that leads to a signifi - cant improvement in both overall survival and progression-free  survival in patients with advanced HCC.",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
289 Jung Gil Park  Complete remission of advanced HCC after sorafenib http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.287cohort are shown in Table 1.,Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
"290 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.287Clin Mol Hepatol Volume _21  Number _3  September 2015function was relatively good (Child-Pugh Class A: 4, Class B: 3).",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
291 Jung Gil Park  Complete remission of advanced HCC after sorafenib http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.287sorafenib because of infection (Table 5).,Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
"292 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.287Clin Mol Hepatol Volume _21  Number _3  September 2015and North America in 2007, the first case in which CR was  achieved in a patient with hemochromatosis and metastatic HCC  after sorafenib monotherapy was reported in 2008.15 At present,  to our knowledge, there have been reports of 13 patients with  advanced HCC who experienced CR after sorafenib monotherapy,  worldwide, excluding 1 pilot analysis conducted in Japan.12,15-24 A  nationwide survey conducted in Japan reported 18 cases of CR  after sorafenib in patients with advanced HCC among 3047 pa - tients (CR rate, 0.6%).25 In the entire cohort of 523 patients in the  present study, only 7 patients (1.3%) achieved CR after sorafenib  therapy.",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
293 Jung Gil Park  Complete remission of advanced HCC after sorafenib http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.287Conflicts of Interest The author has no conflicts to disclose.,Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
"294 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.287Clin Mol Hepatol Volume _21  Number _3  September 2015fani F, et al.",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/cmh-21-287.PMC4612290.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.295 Clinical and Molecular Hepatology 2015;21:295-299 Case Report Corresponding author :  Hyo Keun Lim Department of Radiology, Samsung Medical Center, Sungkyunkwan  University School of Medicine and Department of Health Sciences and  Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea Tel: +82.2-3410-2505, Fax: +82.2-3410-2559 E-mail: rfalim@skku.edu Abbreviations:   ESR, erythrocyte sedimentation rate; IVBCL, intravascular large B-cell  lymphoma; LDH, lactate dehydrogenase  Received :  Aug. 22, 2013 /  Revised :  Oct. 29, 2013 /  Accepted :  Oct. 30, 2013INTRODUCTION  Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype  of extranodal diffuse large B-cell lymphoma.",Non-OADS,/arxiv_data1/oa_pdf/ab/27/cmh-21-295.PMC4612291.pdf
"(Clin Mol Hepatol 2015;21:295-299) Keywords:  Liver neoplasm; Lymphoma; Diagnosis Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ab/27/cmh-21-295.PMC4612291.pdf
296 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.295Clin Mol Hepatol Volume _21  Number _3  September 2015six-week history of dyspnea and a one-day history of fever.,Non-OADS,/arxiv_data1/oa_pdf/ab/27/cmh-21-295.PMC4612291.pdf
Intravascular large B-cell lymphoma http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.295row biopsy was performed and the final pathologic diagnosis was  IVLBCL.,Non-OADS,/arxiv_data1/oa_pdf/ab/27/cmh-21-295.PMC4612291.pdf
298 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.295Clin Mol Hepatol Volume _21  Number _3  September 2015is undermined.9   Laboratory findings are not specific but indicative for suspected  IVLBCL.,Non-OADS,/arxiv_data1/oa_pdf/ab/27/cmh-21-295.PMC4612291.pdf
Intravascular large B-cell lymphoma http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.295tosis and amyloidosis.,Non-OADS,/arxiv_data1/oa_pdf/ab/27/cmh-21-295.PMC4612291.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.300 Clinical and Molecular Hepatology 2015;21:300-308 Case Report Corresponding author :  Chang Hyeong Lee Department of Internal Medicine, Catholic University of Daegu School of  Medicine, 17-33 Duryugongwon-ro, Namgu, Daegu 42472, Korea Tel: +82-53-650-4043, Fax: +82-53-623-7507 E-mail: chlee1@cu.ac.krAbbreviations:   AFP , alpha-fetoprotein; CHB, chronic hepatitis B; CHCC-CC, combined  hepatocellular carcinoma and cholangiocarcinoma; HBV, hepatitis B  virus; hCG, human chorionic gonadotropin; PET, positron emission  tomography Received :  Oct. 16, 2013 /  Revised :  Feb. 14, 2014 /  Accepted :  Feb. 21, 2014INTRODUCTION  Most cases of hepatoblastoma are found under age two, and  occurrence in adults is extremely rare.1,2 There are only 45 report - ed cases of adult hepatoblastoma globally,3-5 and only 3 cases in  Korea.2,6,7 Most of the cases are asymptomatic and might be diag - nosed at late stages of the disease.2,8 Complete surgical resection  is essential in the treatment of hepatoblastoma and standardized  chemotherapy which reduces tumor size increases resectabilities,9 but not so many experiences in adult hepatoblastoma makes it  difficult to occur complete remission.",Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
"(Clin Mol Hepatol 2015;21:300-308) Keywords:  Hepatoblastoma; Surgery; Chemotherapy Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
A case of hepatoblastoma in adult http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300CASE REPORT A 36-year-old female presented at the emergency department  with aggravating right upper abdominal pain for 2 hours.,Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
302 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300Clin Mol Hepatol Volume _21  Number _3  September 2015time of discharge.,OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
A case of hepatoblastoma in adult http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300Figure 4 .,Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
"304 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300Clin Mol Hepatol Volume _21  Number _3  September 2015DISCUSSION Hepatoblastoma is a highly malignant tumor occurring in in - fants, and reports of adult cases are extremely rare.",Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
A case of hepatoblastoma in adult http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300agnosed by H&E stain in a pregnant woman.,Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
306 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300Clin Mol Hepatol Volume _21  Number _3  September 2015blastoma by histologic re-examination with immunohistochemistry  stain.,Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
"A case of hepatoblastoma in adult http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300survival time of 2 cases were about 25 days and 2 months after  surgery.2,7 The one case could not be identified.6 But, our case  showed that survival time was extended 12 months after the cis - platin, 5-FU, vincristine of 3 cycles chemotherapy and carboplatin,  doxofubicin of 4 cycles chemotherapy.",Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
308 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.300Clin Mol Hepatol Volume _21  Number _3  September 20153464.,Non-OADS,/arxiv_data1/oa_pdf/22/b9/cmh-21-300.PMC4612292.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.309 Clinical and Molecular Hepatology 2015;21:309-313 Liver Pathology Corresponding author :  Young Nyun Park Department of Pathology, Yonsei University College of Medicine,   50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-1678, Fax: +82-2-362-0860 E-mail: young0608@yuhs.acAbbreviations:   CC, cholangiocarcinoma; EMT, epithelial–mesenchymal transition; HCC,  hepatocellular carcinomaINTRODUCTION  Cholangiocarcinoma (CC) is an adenocarcinoma arising from  epithelial cells of varying locations within the biliary tree, and is  the second most common primary liver tumor, accounting for ap - proximately 10-15% of all hepatobiliary malignancies.1 This dis - ease has a high prevalence in Southeast and Eastern Asia, includ - ing Korea; during the period 2003-2005, the age-standardized  incidence rates of intrahepatic CC and extrahepatic CC were re - ported to be 6.9 and 5.2 out of 100,000 in Korea, respectively.2  Sarcomatoid carcinoma is a rare tumor composed of mixed malig - nant epithelial and mesenchymal cells, and it can occur in various  organs including liver.",Non-OADS,/arxiv_data1/oa_pdf/a3/21/cmh-21-309.PMC4612293.pdf
"Tumor Sarcomatoid cholangiocarcinoma with osteoclast-like  giant cells associated with hepatolithiasis: A case report Hye Min Kim1, Haeryoung Kim2, and Young Nyun Park1 1Department of Pathology, Yonsei University College of Medicine, Seoul; 2Department of Pathology, Seoul National University Bundang  Hospital, Seoul National University College of Medicine, Seongnam, Korea Keywords:  Sarcomatoid cholangiocarcinoma; Osteoclast-like giant cells; Pathology Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a3/21/cmh-21-309.PMC4612293.pdf
310 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.309Clin Mol Hepatol Volume _21  Number _3  September 2015marker tests revealed elevated carbohydrate antigen 19-9 (1598.0  U/mL) and carcinoembryonic antigen (109.60 ng/mL) levels.,Non-OADS,/arxiv_data1/oa_pdf/a3/21/cmh-21-309.PMC4612293.pdf
"Sarcomatoid cholangiocarcinoma http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.309nucleoli, slightly eosinophilic and granular cytoplasm, and some  mitosis (Fig.",Non-OADS,/arxiv_data1/oa_pdf/a3/21/cmh-21-309.PMC4612293.pdf
"312 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.309Clin Mol Hepatol Volume _21  Number _3  September 2015changes including enhanced migratory capacity, invasiveness, ele - vated resistance to apoptosis, and increased production of extra - cellular matrix components.",Non-OADS,/arxiv_data1/oa_pdf/a3/21/cmh-21-309.PMC4612293.pdf
"Sarcomatoid cholangiocarcinoma http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.309of patients with hepatolithiasis develop CC.17 Repeated episodes  of cholangitis due to hepatolithiasis are considered to induce pro - liferative epithelial changes and accelerate tumorigenesis.18 The prognosis of CC is generally unfavorable because of fre - quent metastasis, low resectability rate and high incidence of re - currence even after curative resection.",Non-OADS,/arxiv_data1/oa_pdf/a3/21/cmh-21-309.PMC4612293.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2015.21.3.314 Clinical and Molecular Hepatology 2015;21:314-317 Liver Imaging Corresponding author :  Kyoung Won Kim Department of Radiology, Asan Medical Center, University of Ulsan  College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82-2-3010-4385, Fax: +82-2-476-4719 E-mail: kimkw@amc.seoul.krAbbreviations:   AST, aspartate aminotransferase; ALT, alanine aminotransferase; SMV,  superior mesenteric vein; IMV, inferior mesenteric veinINTRODUCTION  After liver transplantation, maintaining adequate portal flow  secures nutrients and stimuli essential for the graft.",Non-OADS,/arxiv_data1/oa_pdf/63/4c/cmh-21-314.PMC4612294.pdf
"(Clin Mol Hepatol 2015;21:314-317) Keywords:  Liver transplantation; Portosystemic shunt; Portal flow steal; Doppler Copyright © 2015 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/63/4c/cmh-21-314.PMC4612294.pdf
Portal flow steal after liver transplantation http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.314after.,Non-OADS,/arxiv_data1/oa_pdf/63/4c/cmh-21-314.PMC4612294.pdf
"316 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.314Clin Mol Hepatol Volume _21  Number _3  September 2015cessfully embolizing the IMV using multiple coils and lipiodol, final  portogram demonstrated no residual portal steal and all the flow  from the SMV was directed to the graft (Fig.",Non-OADS,/arxiv_data1/oa_pdf/63/4c/cmh-21-314.PMC4612294.pdf
"Portal flow steal after liver transplantation http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.314Y, et al.",OADS,/arxiv_data1/oa_pdf/63/4c/cmh-21-314.PMC4612294.pdf
"© Alison Kurimchak and Xavier Grana *Correspondence to: Xavier Gra ~na; Email: xgrana@temple.edu Submitted: 08/19/2014; Revised: 10/29/2014; Accepted: 11/03/2014http://dx.doi.org/10.4161/15384101.2014.985069 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes Dev 2004; 18:2699-711; PMID:15545627; http://dx.doi.org/ 10.1101/gad.1256504 2.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 2005; 24:2787-95; PMID:15838515; http://dx.doi.org/10.1038/sj.onc.12086114.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Development 2013; 140:3079- 93; PMID:23861057; http://dx.doi.org/10.1242/dev.091744 5.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
2013; 14:297-306; PMID:23594950; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Exp Cell Res 2001; 264:135-47; PMID:11237530; http://dx.doi.org/ 10.1006/excr.2000.5135 10.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Trends Genet 1998; 14:223-9; PMID:9635405; http://dx.doi.org/ 10.1016/S0168-9525(98)01470-X 11.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell Div 2010; 5:9; PMID:20359370; http://dx.doi.org/10.1186/1747-1028-5-9 12.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 1998; 17:3365-83; PMID:9916999; http://dx.doi.org/10.1038/sj.onc.1202575 13.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
"Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins.Cell 1989; 56:67-75; PMID:2521301; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Virology 1985; 147:142-53; PMID:2932846; http://dx.doi.org/10.1016/0042- 6822(85)90234-X 16.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Science 1989; 243:934-7; PMID:2537532; http://dx.doi.org/ 10.1126/science.2537532 17.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Nature 1998; 391:859-65; PMID:9495340; http://dx.doi.org/10.1038/ 36038 19.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Adv Cancer Res 2001; 82:1-54; PMID:11447760; http://dx.doi.org/10.1016/S0065- 230X(01)82001-7 20.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 2003; 22:2443-51; PMID:12717421;http://dx.doi.org/10.1038/sj.onc.1206339 28.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes Dev 2002; 16:2946-57; PMID:12435635; http://dx.doi.org/10.1101/gad.1011202 29.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
"Genes & Development 1995; 9:1340-53; PMID:7797074; http://dx.doi.org/ 10.1101/gad.9.11.1340 31. Henley SA, Dick FA.",Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell Div 2012; 7:10;PMID:22417103; http://dx.doi.org/10.1186/1747- 1028-7-10 32.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 1999; 97:53-61; PMID:10199402; http://dx.doi.org/10.1016/S0092-8674(00)80714-X 33.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes Dev 1997; 11:1447-63; PMID:9192872;http://dx.doi.org/10.1101/gad.11.11.1447 34.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2005; 25:8166-78; PMID:16135806; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 2006; 127:871-4; PMID:17129771; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Nat Rev Mol Cell Biol 2013; 14:518-28; PMID:23877564; http://dx.doi.org/10.1038/nrm3629 37.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cancer Cell 2002; 2:463-72; PMID:12498715; http://dx.doi.org/10.1016/S1535- 6108(02)00207-6 39.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2013; 33:3330-42; PMID:23775125; http://dx.doi.org/10.1128/MCB.00082-13 40.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2001; 21:1384-92; PMID:11158323; http://dx.doi.org/10.1128/ MCB.21.4.1384-1392.2001 41.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell 2000; 6:729-35; PMID:11030352;http://dx.doi.org/10.1016/S1097-2765(00)00071-X 42.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Gene 2012; 499:1-7;PMID:22387205; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes & Development 1993; 7:555-69; PMID:8384581; http://dx.doi.org/10.1101/gad.7.4.555 45.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 1997; 14:2407-15; PMID:9188855; http://dx.doi.org/10.1038/sj.onc.1201081 46.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 1997;272:4528-35; PMID:9020179; http://dx.doi.org/ 10.1074/jbc.272.7.4528 47.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Curr Eye Res 2002; 24:392-6; PMID:12434308; http://dx.doi.org/ 10.1076/ceyr.24.5.392.8524 48.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 2003; 278:19509-17; PMID:12621062; http://dx.doi.org/ 10.1074/jbc.M300511200 49.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 1999; 18:515-24; PMID:9927208; http://dx.doi.org/10.1038/sj.onc.1202316 50.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 1999; 18:679-88; PMID:9989818; http://dx.doi.org/10.1038/sj.onc.1202289 52.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes Cancer 2013; 3:739-48; PMID:23634261; http://dx.doi.org/10.1177/ 1947601912473479 55.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Biochemistry 1987; 26:7215-20; PMID:2827745; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 1997; 15:911-7; PMID:9285686; http://dx.doi.org/ 10.1038/sj.onc.1201259 58.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Science 1992; 257:1261-4;PMID:1325671; http://dx.doi.org/10.1126/ science.1325671 59.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 2007; 282:26971-80; PMID:17635907; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 1999; 274:14382-91; PMID:10318862; http://dx.doi.org/10.1074/ jbc.274.20.14382 63.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 2008; 133:154- 63; PMID:18394995; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Biochem J 2004; 380:111-9; PMID:14748741; http://dx.doi.org/10.1042/ BJ20031643 67.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 2006; 281:6349-57; PMID:16380387; http://dx.doi.org/10.1074/jbc.M50776020068.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Embo j 2000; 19:5682-91; PMID:11060019; http://dx.doi.org/10.1093/emboj/19.21.5682 69.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Biochem J 1999; 339(Pt 2):241-6; PMID:10191253;http://dx.doi.org/10.1042/0264-6021:3390241 70.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Biol Cell 2001; 12:185-99; PMID:11160832; http://dx.doi.org/10.1091/mbc.12.1.185 71.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Biochem Biophys Res Commun 2007;354:1052-7; PMID:17274953; http://dx.doi.org/ 10.1016/j.bbrc.2007.01.085 72.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 2009; 139:468-84; PMID:19879837; http://dx.doi.org/10.1016/j.cell.2009.10.006 73.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Biochemistry 1990; 29:3166-73; PMID:2159327; http://dx.doi.org/10.1021/ bi00465a002 74.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Biochem J 2003; 369:387-98; PMID:12370081; http://dx.doi.org/ 10.1042/BJ20021244 75.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 1999; 96:99- 110; PMID:9989501; http://dx.doi.org/10.1016/S0092-8674(00)80963-0 76.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Nature 2007;445:53-7; PMID:17086192; http://dx.doi.org/ 10.1038/nature05351 77.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell2008; 31:873-85; PMID:18922469; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell Res 2013; 23:931-46; PMID:23752926; http://dx.doi.org/ 10.1038/cr.2013.77 79.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 2006; 127:1239-51; PMID:17174897; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell 2009; 33:537-45; PMID:19285938; http://dx.doi.org/10.1016/j.molcel.2009.02.015 81.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 2006; 127:341-53; PMID:17055435; http://dx.doi.org/10.1016/j.cell.2006.09.02582.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 2010; 285:29863-73; PMID:20663872; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Life Sci 2010; 87:659-66; PMID:20934435; http://dx.doi.org/10.1016/j.lfs.2010.10.003 84.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Biochemistry 2010; 49:986-95; PMID:20017541; http://dx.doi.org/ 10.1021/bi902160t 85.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 2003; 278:10697-706; PMID:12524438; http://dx.doi.org/10.1074/jbc.M211717200 86.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2000; 20:1021- 9; PMID:10629059; http://dx.doi.org/10.1128/ MCB.20.3.1021-1029.2000 88.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J BiolChem 2008; 283:16104-14; PMID:18397887; http://dx.doi.org/10.1074/jbc.M710313200 89.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2008; 28:873-82; PMID:17991896; http://dx.doi.org/10.1128/ MCB.00480-07 90.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 2000; 275:5257-63; PMID:10681496; http://dx.doi.org/ 10.1074/jbc.275.8.5257 91.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Proteomics 2009; 8:157-71; PMID:18782753; http://dx.doi.org/10.1074/mcp.M800266-MCP200 92.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Int J Biochem Cell Biol 2014; 47:118-48;PMID:24333164; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
17:1051-7; PMID:20694007; http://dx.doi.org/ 10.1038/nsmb.1868 95.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Cell Physiol 2006; 206:495-502; PMID:16206244; http://dx.doi.org/ 10.1002/jcp.20490 96.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Cell Physiol 2011; 226:1027-34; PMID:20857408; http://dx.doi.org/10.1002/ jcp.22418 97.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Cell 2002; 110:19-32;PMID:12150994; http://dx.doi.org/10.1016/S0092- 8674(02)00801-2 98.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Cell Sci 2009; 122:1248- 57; PMID:19339557; http://dx.doi.org/10.1242/jcs.039552 100.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Cell Biol 2003; 161:1053-66; PMID:12821644; http://dx.doi.org/10.1083/ jcb.200302075 102.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes & Devel- opment 1996; 10:1633-44; PMID:8682294; http://dx.doi.org/10.1101/gad.10.13.1633 103.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Cell Biol 2002; 158:741-50; PMID:12177046; http://dx.doi.org/10.1083/jcb.200205025 104.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes & Development 1996; 10:1621-32; PMID:8682293; http://dx.doi.org/10.1101/gad.10.13.1621105.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes Dev 2002; 16:1446-65; PMID:12080084; http://dx.doi.org/10.1101/gad.990702 106.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Pediatr Neph- rol 2010; 25:625-31; PMID:19949815; http://dx.doi.org/10.1007/s00467-009-1368-6 107.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells.Exp Cell Res 2004; 297:152-64; PMID:15194433; http://dx.doi.org/10.1016/j.yexcr.2004.03.011 109.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Cell Physiol 2006; 207:800-8; PMID:16523491; http://dx.doi.org/10.1002/ jcp.20620 111.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2007; 27:5161-71;PMID:17502351; http://dx.doi.org/10.1128/ MCB.02431-06 112.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes & Dev 1997; 11:973-83; PMID:9136926; http://dx.doi.org/10.1101/ gad.11.8.973 113.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
JBiol Chem 2001; 276:29347-52; PMID:11384971; http://dx.doi.org/10.1074/jbc.M101859200 114.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2013; 33:2865-78; PMID:23716589; http://dx.doi.org/10.1128/MCB.01730-12 115.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Nat Cell Biol 2009; 12:886-93; PMID:20711181; http://dx.doi.org/10.1038/ncb20 116.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
J Biol Chem 2005;280:42644-54; PMID:16239230; http://dx.doi.org/ 10.1074/jbc.M502464200 117.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Nat Rev Cancer 2013; 13:585-95; PMID:23842645; http://dx.doi.org/10.1038/ nrc3556 118.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell 2007; 26:539-51; PMID:17531812; http://dx.doi.org/10.1016/j.molcel.2007.04.015 119.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Oncogene 2007; 26:7535-43;PMID:17563750; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes Dev 2012; 26:474-89; PMID:22391450; http://dx.doi.org/ 10.1101/gad.181933.111 121.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Genes Dev 2011; 25:801-13;PMID:21498570; http://dx.doi.org/10.1101/ gad.2034211 122.,OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
Mol Cell Biol 2014; 34(12):2221-34; PMID:24710275; http://dx.doi.org/10.1128/MCB.01523-13 123.,Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
"Lorca T, Castro A. Deciphering the New Role of the Greatwall/PP2A Pathway in Cell Cycle Control.Genes Cancer 2012; 3:712-20; PMID:23634258; http://dx.doi.org/10.1177/1947601912473478 125.",Non-OADS,/arxiv_data1/oa_pdf/2e/02/kccy-14-01-985069.PMC4612414.pdf
"7,8,36-38 © Tomoyuki Hatano, Susumu Morigasaki, Hisashi Tatebe, Kyoko Ikeda, and Kazuhiro Shiozaki *Correspondence to: Kazuhiro Shiozaki; E-mail: kaz@bs.naist.jpSubmitted: 10/16/2014; Revised: 12/15/2014; Accepted: 12/15/2014 http://dx.doi.org/10.1080/15384101.2014.1000215 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Curr Biol 2004;14:1296-302; PMID:15268862; http://dx.doi.org/ 10.1016/j.cub.2004.06.054 5.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Cell 2006; 124:471-84; PMID:16469695; http://dx.doi.org/10.1016/j.cell.2006.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Genes Dev 2001; 15:807-26; PMID:11297505; http://dx.doi.org/ 10.1101/gad.887201 7.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Science 2005; 307:1098-101; PMID:15718470; http://dx.doi.org/10.1126/science.1106148 8.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Dev Cell 2006; 11:859-71; PMID:17141160; http://dx.doi.org/10.1016/j.devcel.2006.10.007 9.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Biochem J 2008;416:375-85; PMID:18925875; http://dx.doi.org/ 10.1042/BJ20081668 10.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
EMBO J 2008; 27:1919-31; PMID:18566587; http://dx.doi.org/10.1038/emboj.2008.119 11.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Biochem J 2008; 410:19-37; PMID:18215152; http://dx.doi.org/10.1042/BJ2007 151812.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
EMBO Rep 2012; 13:121-8; PMID:22240970; http://dx.doi.org/10.1038/embor.2011.257 13.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017 14.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Biol Chem 2001; 276:7027-32; PMID:11096119; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
EMBO J 2003; 22:3073-83; PMID:12805221; http://dx.doi.org/10.1093/emboj/cdg298 17.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Genes Cells2007; 12:1357-70; PMID:18076573; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Genetics 2007;175:1153-62; PMID:17179073; http://dx.doi.org/ 10.1534/genetics.106.064170 19.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Cell Cycle 2008; 7:358-64; PMID:18235227; http://dx.doi.org/10.4161/cc.7.3.5245 20.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Crit Rev Biochem Mol Biol 2008; 43:277-83; PMID:18756382; http://dx.doi.org/10.1080/10409 230802254911 21.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Curr Biol 2010; 20:1975-82;PMID:21035342; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Mol Cell Biol 2007; 27:3154-64; PMID:17261596; http://dx.doi.org/10.1128/ MCB.01039-06 23.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Science1997; 277:99-101; PMID:9204908; http://dx.doi.org/ 10.1126/science.277.5322.99 24.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Nat Rev Mol Cell Biol 2009; 10:307-18; PMID:19339977; http://dx.doi.org/ 10.1038/nrm2672 27.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Mol Biol Cell 2009; 20:1981-91; PMID:19211835; http://dx.doi.org/10.1091/mbc.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Mol Biol Cell 2009; 20:1992-2003; PMID:19225151;http://dx.doi.org/10.1091/mbc.E08-12-1249 29.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Nat Cell Biol 2013; 15:555-64; PMID:23728461; http://dx.doi.org/10.1038/ncb2763 31.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Biochem 2013; 154:1-10; PMID:23698095; http://dx.doi.org/10.1093/jb/ mvt047 32.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Genes Cells 2006; 11:1367-79; PMID:17121544; http://dx.doi.org/10.1111/j.1365-2443.2006.01025.x 33.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Cell Sci 2010; 123:777-86; PMID:20144990; http://dx.doi.org/10.1242/ jcs.060319 34.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Cell Sci 2012; 125:5840-9; PMID:22976295; http://dx.doi.org/10.1242/jcs.111146 35.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Dev Cell 2006; 11:583-9; PMID:16962829; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Cell 2006;127:125-37; PMID:16962653; http://dx.doi.org/ 10.1016/j.cell.2006.08.033 38.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Cell Cycle 2011; 10:2305-16; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Cell Sci2006; 119:4475-85; PMID:17046992; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Microbiology 2009; 155:3816-26; PMID:19778961;http://dx.doi.org/10.1099/mic.0.034389-0 47.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Genes Cells 2012; 17:698-708; PMID:22762302; http://dx.doi.org/10.1111/j.1365- 2443.2012.01618.x 48.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
FEBS J 2011; 278:1299- 315; PMID:21306563; http://dx.doi.org/10.1111/ j.1742-4658.2011.08050.x 50.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Biol Chem 2009; 284:2628-35; PMID:19019823; http://dx.doi.org/10.1074/jbc.M806003200 54.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Cell 2007; 129:1261-74; PMID:17604717; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Curr Opin Cell Biol 2005; 17:596-603; PMID:16226444; http://dx.doi.org/10.1016/j.ceb.2005.09.009 57.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Mol Cell Biol 2009; 29:1411-20;PMID:19114562; http://dx.doi.org/10.1128/ MCB.00782-08 58.,Non-OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Biol Chem 2011; 286:10998-1002; PMID:21310961; http://dx.doi.org/10.1074/jbc.M110.195016 59.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Science 2001; 294:1102-5; PMID:11691993; http://dx.doi.org/10.1126/science.1063518 61.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Biol Chem 2014; PMID:24928510; http://dx.doi.org/10.1074/jbc.M114.573824 62.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
J Cell Biol 2013; 203:595-604; PMID:24247430; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Yeast 1998; 14:943-51; PMID:9717240; http://dx.doi.org/10.1002/(SICI)1097-0061(199807)14:10 <943::AID- YEA292 >3.0.CO;2-Y 64.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Yeast 2001; 18:207-17; PMID:11180454; http://dx.doi.org/10.1002/1097-0061(200102)18:3 <207::AID-YEA661 >3.0.CO;2-I 68.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
Small GTPases 2010; 1:180-2; PMID:21625337; http://dx.doi.org/10.4161/sgtp.1.3.14936 70.,OADS,/arxiv_data1/oa_pdf/ea/35/kccy-14-06-1000215.PMC4612450.pdf
"HER2 ampliﬁcation is observed in 15–20% of human breast cancers14and has been generally associated with poor survival.15In vitro , HER2 ampliﬁ- cation has been shown to increase cellular resistance to taxanes inbreast cancer cells, 16while a number of clinical studies have shown HER2 ampliﬁcation to correlate with increased response *Correspondence to: Graham Dellaire; Email: dellaire@dal.ca Submitted: 12/09/2014; Accepted: 01/07/2014 http://dx.doi.org/10.1080/15384101.2015.1007775 www.tandfonline.com 1059 Cell CycleCell Cycle 14:7, 1059--1069; April 1, 2015; © 2015 Taylor & Francis Group, LLCREPORT",Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Nature 1986; 324:485-9; PMID:2878368; http://dx.doi.org/10.1038/324485a0 5.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
JNatl Cancer Inst 1997; 89:917-31; PMID:9214671; http://dx.doi.org/10.1093/jnci/89.13.917 8.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Oncogene 2003; 22:7280-95; PMID:14576838; http://dx.doi.org/10.1038/sj.onc.1206934 9.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Cancer Res 2004; 64:2502-8; PMID:15059905; http://dx.doi.org/10.1158/0008- 5472.CAN-03-2013 11.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Cyclin A-associ- ated kinase activity is needed for paclitaxel sensitivity.Mol Cancer Ther 2005; 4:1039-46; PMID:16020661; http://dx.doi.org/10.1158/1535-7163.MCT-04-0282 12.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Am J Pathol 2003; 163:1109-16; PMID:12937152; http://dx.doi.org/10.1016/S0002- 9440(10)63470-0 14.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Clin Cancer Res 2008; 14:8019-26; PMID:19088018; http://dx.doi.org/ 10.1158/1078-0432.CCR-08-0974 15.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Breast Cancer Res Treat 2004; 86:197-206; PMID:15567936; http://dx.doi.org/ 10.1023/B:BREA.0000036783.88387.47 19.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
J Natl Cancer Inst 2004; 96:1141-51;PMID:15292386; http://dx.doi.org/10.1093/jnci/ djh198 20.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
N Engl J Med 2005; 352:2302-13;PMID:15930421; http://dx.doi.org/10.1056/ NEJMoa043681 21.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
N Engl J Med 2007; 357:1496-506; PMID:17928597; http://dx.doi.org/ 10.1056/NEJMoa071167 22.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
J Exp Clin Can-cer Res 2011; 30:38; PMID:21481270; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Mol Cell Biol 2002; 22:5141-56; PMID:12077342; http://dx.doi.org/10.1128/MCB.22.14.5141-5156.2002 24.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Nat Struct Mol Biol 2010; 17:216-21; PMID:20118938; http://dx.doi.org/10.1038/nsmb.1718 25.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
J Cell Biol 2007; 179:601-9; PMID:17998396;http://dx.doi.org/10.1083/jcb.200703133 26.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Cancer Cell 2007; 11:498-512; PMID:17560332; http://dx.doi.org/ 10.1016/j.ccr.2007.04.011 27.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Mol Cancer Ther 2008; 7:2377-85; PMID:18687998; http://dx.doi.org/ 10.1158/1535-7163.MCT-08-0316 28.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
J Biol Chem 2013; 288:30125-38; PMID:24003220; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Cancer Epidemiol Biomarkers Prev2008; 17:913-20; PMID:8398031UND; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Cancer Cell 2004; 6:459-69; PMID:15542430; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
J Thorac Cardiovasc Surg 2004; 127:365-75; PMID:14762343; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
J Cell Sci 2009; 122:2579-85;PMID:19625502; http://dx.doi.org/10.1242/ jcs.039719 34.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
BMC Cancer 2012; 12:379; PMID:22931248; http://dx.doi.org/10.1186/1471-2407-12-379 35.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Gynecol Oncol 2004; 92:31-9; PMID:14751135; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
N Engl J Med 2001;344:783-92; PMID:11248153; http://dx.doi.org/ 10.1056/NEJM200103153441101 38.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
N Engl J Med 2005; 353:1673-84; PMID:16236738; http://dx.doi.org/10.1056/NEJMoa052122 39.,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
J Clin Oncol 2012; 30:1989-95; PMID:22493419; http://dx.doi.org/10.1200/JCO.2011.39.0823 1068 Volume 14 Issue 7 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Nature 1998; 392:300-3; PMID:9521327; http://dx.doi.org/10.1038/32688 42.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
PloS One 2012; 7:e38541; PMID:22685580; http://dx.doi.org/ 10.1371/journal.pone.0038541 44.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Circulation 2000; 102:1221-6; PMID:10982534; http://dx.doi.org/10.1161/01.CIR.102.11.122145.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Hum Mutat 2009; 30:1123-33; PMID:19388116; http://dx.doi.org/10.1002/ humu.21029 46.,Non-OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
Exp Cell Res 2013; 319:2554-65; PMID:24036361; http://dx.doi.org/10.1016/j.yexcr.2013.09.001 www.tandfonline.com 1069 Cell Cycle,OADS,/arxiv_data1/oa_pdf/b3/bd/kccy-14-07-1007775.PMC4612451.pdf
"ﬁscher@medizin.uni-leipzig.de; Kurt Engeland; Email: engeland@medizin.uni-leipzig.de Submitted: 07/08/2014; Accepted: 07/10/2014 http://dx.doi.org/10.4161/15384101.2014.949083 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nat Rev Cancer 2009; 9:749-58; http://dx.doi.org/10.1038/ nrc2723; PMID:19776744 3.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nat Rev Cancer 2009;9:724-37; PMID:19776742; http://dx.doi.org/ 10.1038/nrc2730 5.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2011; 6(3):e17574; PMID:21394211;http://dx.doi.org/10.1371/journal.pone.0017574 7.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Death Differ 2012; 19:1992-2002; PMID:22790872; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2013; 41:7286-301;http://dx.doi.org/10.1093/nar/gkt504 9.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Scientometrics2012; 90:891-904; http://dx.doi.org/10.1007/ s11192-011-0494-7 13.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cold Spring Harb Perspect Biol 2010; 2:a000935; PMID:20679336; http://dx.doi.org/ 10.1101/cshperspect.a000935 16.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biomed Biotechnol 2011; 2011:464916; PMID:21436991; http://dx.doi.org/ 10.1155/2011/464916 17.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Trends Cell Biol 2011; 21:344-53; PMID:21601459; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Tackling the widespread and critical impact of batch effects in high-throughput data.Nat Rev Genet 2010; 11 733-9; PMID:20838408; http://dx.doi.org/10.1038/nrg2825 19.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Molecular Oncology 2011; 5:336-48; PMID:21795128; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nature 2012;487:491-5; PMID:22810586; http://dx.doi.org/ 10.1038/nature11288 22.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Death and Differentiation 2013; 20:576-88; PMID:23306555; http://dx.doi.org/10.1038/cdd.2012.155 23.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Hepatol 2012; 56:656-62; PMID:22037227; http://dx.doi.org/10.1016/j.jhep.2011.08.022 24.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Cycle 2011; 10:4237-49; PMID:22127205;http://dx.doi.org/10.4161/cc.10.24.18383 26.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Genes Dev 2013; 27:1016-31; PMID:23651856; http://dx.doi.org/ 10.1101/gad.212282.112 27.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Sci Signal 2014; 7:rs3; PMID:24825921; http://dx.doi.org/10.1126/ scisignal.2005032 28.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"Elife 2014; 3: e02200; PMID:24867637; http://dx.doi.org/ 10.7554/eLife.02200; (b) Janky R, Verfaillie A, Imrichov /C19a H, Van de Sande B, Standaert L, et al.",OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
e1003731; PMID:25058159; http://dx.doi.org/ 10.1371/journal.pcbi.100373 29.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
BMC Genomics 2008; 9:486; PMID:18922183; http://dx.doi.org/10.1186/1471- 2164-9-486 40.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Neurosci Res 2009; 87 887-905; PMID:18951482; http://dx.doi.org/10.1002/jnr.21910 41.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
FEBS J 2009; 276:2201-12; PMID:19302216; http://dx.doi.org/10.1111/j.1742- 4658.2009.06949.x 66.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"Sohr S, Engeland K. The tumor suppressor p53 induces expression of the pregnancy-supporting human chorionic gonadotropin (hCG) CGB7 gene.Cell Cycle 2011; 10:3758-67; PMID:22032922; http://dx.doi.org/10.4161/cc.10.21.17946 76.",OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mole Cancer Res 2008; 6:624-33; PMID:18403641; http://dx.doi.org/10.1158/1541-7786.MCR-07-2019 94.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Genes Dev 2012; 26:1533-45; PMID:22802528; http://dx.doi.org/10.1101/gad.184911.111 99.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2009; 28:3081- 92; PMID:19543321; http://dx.doi.org/10.1038/ onc.2009.154 100.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Res 2009; 69:3405-14; PMID:19351845; http://dx.doi.org/10.1158/0008-5472.CAN-08-3628 104.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"Schilling T, Schleithoff ES, Kairat A, Melino G, Stremmel W, Oren M, Krammer PH, M €uller M. Active transcription of the human FASCD95TNFRSF6 gene involves the p53 family.Biochem Biophys Res Commun 2009; 387:399-404; PMID:19615968; http://dx.doi.org/ 10.1016/j.bbrc.2009.07.063 108.",OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2010; 5(4): e10236; PMID:20422012; http://dx.doi.org/10.1371/journal.pone.0010236 110.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Biochem Bio-phys Res Commun 2013; 436:204-11; PMID:23727578; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Res 2009; 69:6049-56; PMID:19602589; http://dx.doi.org/10.1158/0008-5472.CAN-09-0621 119.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mole Cancer Res 2008; 6 843-50; PMID:18505928; http://dx.doi.org/10.1158/1541-7786.MCR-07-2105 www.landesbioscience.com 3051 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"Song LL, Alimirah F, Panchanathan R, Xin H, Choubeyt D. Expression of an IFN-inducible cellu- lar senescence gene IFI16 Is up-regulated by p53.Mole Cancer Res 2008; 6:1732-41; PMID:18974396; http://dx.doi.org/10.1158/1541- 7786.MCR-08-0208 135.",Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res2009; 37:322-5; PMID:19042971; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell 2011; 44:491-501; PMID:22055193; http://dx.doi.org/10.1016/j.molcel.2011.08.038 142.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Reprod Biol Endocrinol 2009; 7:135; PMID:19939245; http://dx.doi.org/ 10.1186/1477-7827-7-135 147.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2012; 7(9):e44869; PMID:22984579; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2008; 36:7168-80; PMID:19015127; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2009; 28 545-54; PMID:18997816; http://dx.doi.org/10.1038/onc.2008.409 170.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Death Disease 2012; 3:e442; PMID:23235459; http://dx.doi.org/ 10.1038/cddis.2012.180 172.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Biochem Biophys Res Commun 2008; 369:308-13; PMID:18279664; http://dx.doi.org/10.1016/j.bbrc.2008.01.171 174.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2013; 8(7):e69152; PMID:23861960; http://dx.doi.org/10.1371/journal.pone.0069152 175.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Cycle 2013; 12:1279-91; PMID:23535297; http://dx.doi.org/10.4161/cc.24364 177.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Biochem J 2009; 422:363-72; PMID:19534726; http://dx.doi.org/10.1042/ BJ20090465 185.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2008; 283:30689-98;PMID:18779328; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Cycle 2012; 11:4570-8; PMID:23165212; http://dx.doi.org/10.4161/cc.22843 199.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Plos Genetics 2011; 7(3): e1001360; PMID:21483755; http://dx.doi.org/ 10.1371/journal.pgen.1001360 202.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
MolCell Biol 2008; 28:6557-67; PMID:18779317; http://dx.doi.org/10.1128/MCB.01202-08 203.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2013; 41:5614-25; PMID:23595149; http://dx.doi.org/10.1093/nar/gkt222.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Cell Biol 2008; 28:5139-46; PMID:18573881; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2008; 36:1555-66;PMID:18208837; http://dx.doi.org/10.1093/nar/ gkm1173 242.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2009; 28:2046-50; PMID:19363521;http://dx.doi.org/10.1038/onc.2009.62 250.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Embo Journal 2011; 30:3397-415; PMID:21792176; http://dx.doi.org/ 10.1038/emboj.2011.248 252.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2008; 283:29671-80; PMID:18765668; http://dx.doi.org/10.1074/jbc.M802785200 253.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2012; 7 (8):e42615; PMID:22905155; http://dx.doi.org/ 10.1371/journal.pone.0042615 255.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2011; 6 (10):e26156; PMID:22028823; http://dx.doi.org/10.1371/journal.pone.0026156 261.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell 2008; 134:62-73; PMID:18614011; http://dx.doi.org/ 10.1016/j.cell.2008.06.006 263.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Res 2010; 70:5807-17;PMID:20570896; http://dx.doi.org/10.1158/0008- 5472.CAN-09-4161 267.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2009; 37:78-95; PMID:19015155; http://dx.doi.org/10.1093/nar/gkn910 268.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Res 2009; 69:753-7; PMID:19141643; http://dx.doi.org/10.1158/0008-5472.CAN-08-2708 270.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2008; 27: 6866-74; PMID:18820708; http://dx.doi.org/ 10.1038/onc.2008.324 271.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2013; 8(9):e73542; PMID:24023884; http://dx.doi.org/10.1371/journal.pone.0073542 273.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
p53 Directly represses id2 toinhibit the proliferation of neural progenitor cells.Stem Cells 2011; 29:1090-101; PMID:21608079; http://dx.doi.org/10.1002/stem.660 276.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Hepatol 2009; 50:528-37; PMID:19155088; http://dx.doi.org/10.1016/j.jhep.2008.10.025 282.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2013; 288:35940-51; PMID:24163369; http://dx.doi.org/10.1074/jbc.M113.523837 290.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Exp Cell Res 2013; 319:3104-15;PMID:24076372; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nature 2011;470:359-65; PMID:21307849; http://dx.doi.org/ 10.1038/nature09787 301.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2004;23:9336-47; PMID:15531928; http://dx.doi.org/ 10.1038/sj.onc.1208114 302.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Biochem Biophys Res Commun 2008; 369:567-72; PMID:10196169; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Chem 1999; 274:10911-5; PMID:10196169; http://dx.doi.org/10.1074/jbc.274.16.10911 304.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Onco- gene 2009; 28:3787-800; PMID:19749791; http://dx.doi.org/10.1038/onc.2009.143 305.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
B B A-Gene Struct Expr 2004; 1678:111-25; http://dx.doi.org/10.1016/j.bbaexp.2004.03.002 www.landesbioscience.com 3055 Cell Cycle,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Carcinogen 2008; 47:373-82; PMID:17999388;http://dx.doi.org/10.1002/mc.20395 307.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
EMBO Rep2006; 7:219-24; PMID:16322760; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2013; 8:e73817; PMID:24040083; http://dx.doi.org/10.1371/journal.pone.0073817 311.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Res 2004; 64:2627-33; PMID:15059920; http://dx.doi.org/10.1158/0008- 5472.CAN-03-0846 312.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2002; 277:39266- 73; PMID:12163498; http://dx.doi.org/10.1074/jbc.M205939200 313.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2006;281:39776-84; PMID:17077087; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2006; 281:21698-709;PMID:16740634; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Res 2011; 71:6684-95; PMID:22009531; http://dx.doi.org/10.1158/0008-5472.CAN-11-1233 317.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2003; 22:7716-27; PMID:14586398; http://dx.doi.org/10.1038/sj.onc.1207155 318.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J. Biol.Chem 2001; 276:298-305; PMID:11013253; http://dx.doi.org/10.1074/jbc.M007155200 320.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2006; 25:2318- 27; PMID:16501612; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Bmc Cancer 2011; 11; PMID:21791091; http://dx.doi.org/10.1186/ 1471-2407-11-378 324.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
EMBO J2009; 28:2719-32; PMID:19696742; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2001; 276:27716-20; PMID:11350951; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 1999; 274:15237-44; PMID:10329733; http://dx.doi.org/10.1074/jbc.274.21.15237 327.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Febs Lett 2005; 579:1001-7;PMID:15710382; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2009; 37:2688-98; PMID:19273532; http://dx.doi.org/10.1093/nar/ gkp110 329.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"J Biol Chem 2003; 278:37439-50; PMID:12876282;http://dx.doi.org/10.1074/jbc.M307185200 330. de Toledo SM, Azzam EI, Keng P, Laffrenier S, Lit- tle JB.",OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Cell Biol 2000;20:4210-23; PMID:10825186; http://dx.doi.org/ 10.1128/MCB.20.12.4210-4223.2000 333.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Cell Sci 2005; 118:1821-32; PMID:15827088; http://dx.doi.org/10.1242/jcs.02307 336.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Proc Natl Acad Sci USA 1991;88:9979-83; PMID:1946467; http://dx.doi.org/ 10.1073/pnas.88.22.9979 337.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Cell Biol 2013; 33:227-36; PMID:23109430; http://dx.doi.org/10.1128/MCB.00881-12 340.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Cell 2010; 17:376-87; PMID:20385362; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Genes Dev 2012; 26:474-89; PMID:22391450; http://dx.doi.org/10.1101/gad.181933.111 343.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Genes Dev 1998; 12: 2102-7; PMID:9679054; http://dx.doi.org/ 10.1101/gad.12.14.2102 344.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Bio- chem Biophys Res Commun 2001; 284:743-50;PMID:11396965; http://dx.doi.org/10.1006/ bbrc.2001.5040 345.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2014; 33:3959-69; http://dx.doi.org/10.1038/onc.2013.378 346.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Cell Biol 2001; 21:1066-76; PMID:11158294; http://dx.doi.org/10.1128/MCB.21.4.1066-1076.2001 349.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Cell Biol 2006; 26:2501-10; PMID:16537896; http://dx.doi.org/10.1128/MCB.26.7.2501-2510.2006 352.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2009; 28:4295-305; PMID:19749794; http://dx.doi.org/ 10.1038/onc.2009.282 353.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer Cell 2011; 19:701-14; PMID:21665145; http://dx.doi.org/ 10.1016/j.ccr.2011.04.017 354.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Cycle 2012; 11:4661-72; PMID:23187802;http://dx.doi.org/10.4161/cc.22917 356.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2013; 8:e63187; PMID:23650552; http://dx.doi.org/10.1371/ journal.pone.0063187 357.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2014;42:163-80; PMID:24071582; http://dx.doi.org/ 10.1093/nar/gkt849 358.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Cycle 2007; 6:1903-13; PMID:17671431; http://dx.doi.org/10.4161/cc.6.15.4512 359.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cancer 2013; 13:585-95; PMID:23842645; http://dx.doi.org/10.1038/nrc3556 360.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2001;276:1998-2006; PMID:11032828; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2008; 27:2583-93; PMID:17982488; http://dx.doi.org/10.1038/sj.onc.1210898 362.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Febs Lett 1996; 385:34-8; PMID:8641461; http://dx.doi.org/10.1016/0014-5793(96)00330-4 363.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2008; 27:1562-71; PMID:17873905; http://dx.doi.org/10.1038/sj.onc.1210799 364.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2004; PMID:15208672; 23:5759-69; http://dx.doi.org/ 10.1038/sj.onc.1207706 366.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nat Struct Mol Biol 2012; 19:478-84 S1; PMID:22466965; http://dx.doi.org/10.1038/nsmb.2271 368.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"Krause K, Wasner M, Reinhard W, Haugwitz U, Dohna CL, M €ossner J, Engeland K. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000; 28:4410-8; PMID:11071927; http://dx.doi.org/10.1093/nar/ 28.22.4410 369.",OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2007; 26:1949-53; PMID:17001315;http://dx.doi.org/10.1038/sj.onc.1209989 370.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Febs Lett 2007; 581:1166-72; PMID:17336302; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Cycle 2007; 6:853-62; PMID:17377499; http://dx.doi.org/10.4161/cc.6.7.4017 372.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Cycle 2013; 12:11; PMID:23255095; http://dx.doi.org/10.4161/cc.23169 373.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2012; 40:3511-23; PMID:22180533; http://dx.doi.org/10.1093/nar/gkr1203 374.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Science 1989; 243:934-7; PMID:2537532; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Science 1993; 259:84-7; PMID:8418500; http://dx.doi.org/10.1126/science.8418500 380.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 1999; 274:32137-44; PMID:10542249;http://dx.doi.org/10.1074/jbc.274.45.32137 381.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2007; 282:2615-25; PMID:17124180; http://dx.doi.org/10.1074/jbc.M606203200 382.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2003; 278:15652-60; PMID:12591928; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2004; 279:25093-100; PMID:15044452; http://dx.doi.org/10.1074/jbc.M403232200 386.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2004;279:52141-9; PMID:15469934; http://dx.doi.org/ 10.1074/jbc.M407915200 387.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Ph armacol 2013; 83:1229- 36; PMID:23536728; http://dx.doi.org/10.1124/ mol.113.085092 388.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Biochem Biophys Res Commun 2005; 335:1272-9; PMID:16112647;http://dx.doi.org/10.1016/j.bbrc.2005.08.026 389.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell Death Dis 2014; 5:e987; PMID:24407240; http://dx.doi.org/10.1038/cddis.2013.527 392.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2005; 280:4825-33; PMID:15563462; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2002; 21:7478-87; PMID:12386810; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2000; 19:5123-33; PMID:11064449; http://dx.doi.org/10.1038/sj.onc.1203890 396.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Mol Pharmaco 2003;.63:359-67; PMID:12527807; http://dx.doi.org/ 10.1124/mol.63.2.359 398.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2011; 39:76-88; PMID:20805247; http://dx.doi.org/10.1093/nar/gkq762 402.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
PLoS One 2012; 7:e43564; PMID:22952705;http://dx.doi.org/10.1371/journal.pone.0043564403.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 1999; 274:29677-82;PMID:10514438; http://dx.doi.org/10.1074/ jbc.274.42.29677 404.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
J Biol Chem 2003; 278:6642-50; PMID:12482752; http://dx.doi.org/ 10.1074/jbc.M210065200 405.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Science 2010;328:232-5; PMID:20299548; http://dx.doi.org/ 10.1126/science.1183621 407.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
2014;PMID:25106871; http://dx.doi.org/10.1093/nar/ gku696 408.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nucleic Acids Res 2012; 40:1561-78; PMID:22064854; http://dx.doi.org/10.1093/nar/gkr793 409.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2008; 27:5326-38;PMID:18504435; http://dx.doi.org/10.1038/ onc.2008.165 410.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell 1991; 65:1053-61; PMID:1828392; http://dx.doi.org/10.1016/0092-8674(91)90557-F 412.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Oncogene 2003; 22:1445-60; PMID:12629508; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"Elkon R, Linhart C, Sharan R, Shamir R, Shiloh Y. Genome-wide in silico identiﬁcation of transcriptional regulators controlling the cell cycle in human cells.Genome Res 2003; 13:773-80; PMID:12727897; http://dx.doi.org/10.1101/gr.947203 414.",OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
"Linhart C, Elkon R, Shiloh Y, Shamir R, Deciphering transcriptional regulatory elements that encode speciﬁc cell cycle phasing by comparative genomics analysis.Cell Cycle 2005; 4:1788-97; PMID:16294034; http://dx.doi.org/10.4161/cc.4.12.2173 415.",OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
The transcriptional network that controls growth arrest and differentia-tion in a human myeloid leukemia cell line.Nat Genet 2009; 41:553-62; PMID:19377474; http://dx.doi.org/10.1038/ng.375 416.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Nature 2007; 447:1130-4; PMID:17554337; http://dx.doi.org/ 10.1038/nature05939 417.,Non-OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
Cell 2010; 142:409-19; PMID:20673990; http://dx.doi.org/ 10.1016/j.cell.2010.06.040 418.,OADS,/arxiv_data1/oa_pdf/81/29/kccy-13-19-949083.PMC4612452.pdf
